Proteasome inhibitors exacerbate interleukin-8 production induced by protease-activated receptor 2 in intestinal epithelial cells

Cytokine. 2016 Oct:86:41-46. doi: 10.1016/j.cyto.2016.07.014. Epub 2016 Jul 25.

Abstract

Protease activated receptors (PARs) and the ubiquitin-proteasome system (UPS) regulate inflammatory response in intestinal cells. We aimed to elucidate putative connections between PARs and UPS pathways in intestinal epithelial cells. Caco-2 cells were treated by agonist peptides of PARs and/or IL-1β and/or proteasome inhibitors, bortezomib or MG132. Inflammatory response was evaluated by measuring IL-8 production. Proteasome activities were also evaluated. We showed that PAR-1 and -2 activation increased release of IL-8 compared with vehicle and independently of IL-1β. In contrast, PAR-4 agonist peptide had no effect. Caspase-like and chymotrypsin-like proteasomal activities were increased by PAR-2 activation only in the presence of IL-1β. Interestingly, in polarized Caco-2 cells, the release of IL-8 was predominantly upregulated in the side where PAR-2 agonist peptide was added, apical or basalolateral. In contrast, proteasome activities were only affected when PAR-2 agonist peptide was added in the apical side. Proteasome inhibitors, bortezomib and MG132, enhanced IL-8 production in both sides, apical and basolateral. In conclusion, PAR-2 activation alone did not affect proteasome but needed inflammatory stimulus IL-1β to synergistically increase chymotrypsin-like activity in intestinal epithelial cells. However, proteasome inhibition led to exacerbate inflammatory response induced by PAR-2 activation.

Keywords: Interleukin; Intestinal epithelial cells; Protease-activated receptor-2; Proteasome.

MeSH terms

  • Bortezomib / pharmacology
  • Caco-2 Cells
  • Humans
  • Interleukin-1beta / pharmacology
  • Interleukin-8 / biosynthesis*
  • Interleukin-8 / immunology
  • Interleukin-8 / metabolism
  • Intestinal Mucosa / cytology
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / metabolism*
  • Leupeptins / pharmacology
  • Peptides / pharmacology
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors / pharmacology*
  • Receptor, PAR-2 / agonists
  • Receptor, PAR-2 / metabolism*

Substances

  • Interleukin-1beta
  • Interleukin-8
  • Leupeptins
  • Peptides
  • Proteasome Inhibitors
  • Receptor, PAR-2
  • Bortezomib
  • Proteasome Endopeptidase Complex
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde